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ABSTRACT (171 words) 
Cepharanthine, a biscolaurine alkaloid isolated from the plant Stephania cephalantha Hayata, 
has been reported to have potent anti-inflammatory properties. Here we investigated the 
effects of cepharanthine on the expression of CXCL10 (a CXC chemokine induced by 
interferon-gamma [IFN-γ] that has been observed in a wide variety of chronic inflammatory 
disorders and autoimmune conditions) in IFN-γ-treated human salivary gland cell lines. We 
observed that IFN-γ induced CXCL10 production in NS-SV-DC cells (a human salivary gland 
ductal cell line), but not in NS-SV-AC cells (a human salivary gland acinar cell line). 
Cepharanthine inhibited the IFN-γ-induced CXCL10 production in NS-SV-DC cells. A 
Western blot analysis showed that cepharanthine prevented the phosphorylation of JAK2 and 
STAT1, but did not interfere with the NF-κB pathway. Moreover, cepharanthine inhibited the 
IFN-γ-mediated chemotaxis of Jurkat T cells. These results suggest that cepharanthine 
suppresses IFN-γ-induced CXCL10 production via the inhibition of the JAK2/STAT1 
signaling pathway in human salivary gland ductal cells. Our findings also indicate that 
cepharanthine could inhibit the chemotaxis of Jurkat T cells by reducing CXCL10 production. 
 
KEY WORDS: 
Cepharanthine, CXCL10, IFN-γ, JAK/STAT1 signaling, salivary gland ductal cells, primary 
Sjögren's syndrome 
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INTRODUCTION 
Primary Sjögren's syndrome (pSS), one of the most common autoimmune diseases [1], 
is characterized by the eventual total replacement of the acinar structure by marked 
lymphocytic infiltrates in the salivary and lacrimal glands [2]. The pathogenesis of this 
selective and progressive destruction of the acinar structure in salivary glands is not yet fully 
understood. However, accumulated evidence indicates a close relationship between cytokine 
expression in salivary gland tissue and the development and progression of this disease [3, 4]. 
Among several cytokines, especially interferons (IFNs) [5, 6] and tumor necrosis factor-alpha 
(TNF-α) [7], have been suggested to play an important role in the pathogenesis of pSS. 
CXCL10, a CXC chemokine induced by IFN-γ, is produced by diverse cell types, 
including peripheral blood mononuclear cells (PBMC), fibroblasts, and endothelial cells 
during Th1-type immune responses [8]. CXCL10 binds its receptor to CXCR3. CXCR3 is 
widely expressed on multiple types of cells of the innate immune system, including dendritic 
cells, natural killer (NK) cells, NKT cells, neutrophils, and macrophages [9–12]. Thus, these 
entirely different innate immune cells are potential targets for CXCL10-mediated chemotaxis. 
The expression of CXCL10 has been observed in pSS. Ogawa et al. [13, 14] reported 
that Th1 chemokines such as CXCL9, CXCL10, and CXCL11 were involved in the 
accumulation of T-cell infiltrates in the salivary glands of pSS patients. Moreover, the 
inoculation of a CXCL10 antagonist into MRL/lpr mice during the early stage of sialadenitis 
significantly reduced the mononuclear cell infiltration and parenchymal destruction [15]. 
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Cepharanthine (Kaken Pharmaceutical Co. Ltd, Tokyo), a biscoclaurine alkaloid 
extracted from the plant Stephania cephalantha Hayata, has been used widely for the 
treatment of a number of acute and chronic diseases, for leukopenia during radiation therapy, 
and as an anticancer treatment [16]. Although the exact mechanism has not been elucidated, 
cepharanthine exerts immunomodulatory effects by enhancing the cytotoxic effect of NK cells 
and macrophages [17, 18], suggesting that cepharanthine may play a role in the regulation of 
signaling pathways of cytokines. It has been demonstrated that cepharanthine effectively 
suppressed TNF-α-induced matrix metalloproteinase (MMP)-9 production, leading to the 
restoration of normal acinar structures in both an in vitro culture system and an in vivo murine 
SS model [19, 20]. Additionally, a single-center open-label study showed efficacy of 
cepharanthine on the increase of salivary flow in pSS patients [21]. However, an analysis to 
identify the influence of cepharanthine on CXCL10 expression in salivary gland cells has not 
been performed. 
We therefore examined the effect of cepharanthine on the regulation of IFN-γ-induced 
CXCL10 expression by using immortalized human salivary gland cell clones in an in vitro 
experiment. We also investigated whether cepharanthine regulates the CXCL10-mediated 
chemotaxis of human T-cell leukemia cells. 
 
MATERIALS AND METHODS 
Cell culture 
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The characteristics of the cell lines NS-SV-DC (immortalized human salivary gland 
ductal cells) and NS-SV-AC (immortalized human salivary gland acinar cells) are described 
in detail elsewhere [22]. These cell clones were cultured at 37°C in serum-free keratinocyte 
medium (Gibco Laboratories, Gaithersburg, MD) in an incubator with an atmosphere 
containing 5% CO2. Jurkat human leukemic T cells (Riken Cell Bank, Ibaraki, Japan) were 
maintained in RPMI-1640 medium (Gibco Laboratories), which was supplemented with 10% 
fetal bovine serum (FBS, Gibco) in a 5% CO2-humidified incubator at 37°C. 
 
Reagents 
Recombinant human IFN-γ was purchased from R&D Systems (Minneapolis, MN). 
Cepharanthine was purchased from Kaken Shoyaku Co. (Tokyo). 
 
Cell growth assay 
NS-SV-DC cells (1×104 cells/ well) and NS-SV-AC cells (1×104 cells/ well) were 
seeded in 96-well plates (Falcon, Oxnard, CA) in serum-free keratinocyte medium. 
Twenty-four hours later, the cells were treated with cepharanthine (0.1–50 μg/ml). After 
appropriate incubation periods, an MTT reagent (Roche, Basel, Switzerland) was added to 
each well and incubation was continued for 4 h. The cells were dissolved in Solubilization 
Solution (Roche) and read at 570 nm in a microtiter plate reader. 
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Enzyme-linked immunosorbent assay (ELISA) 
NS-SV-DC and NS-SC-AC cells were plated onto 96-well plates (1×105 cells/well) and 
treated with various concentrations of IFN-γ for 6, 12, or 24 h. Each concentration of 
CXCL10 was determined by an ELISA kit (R&D Systems) according to the manufacturer's 
instructions. Optimal absorbance was read at 450 nm in a microtiter plate reader. 
 
Quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) 
NS-SV-DC cells were treated with IFN-γ (10 ng/ml) for 6, 12, or 24 h in the presence 
or absence of various concentrations of cepharanthine. Total cellular RNA was isolated with 
TRIzol reagent (Life Technologies, Carlsbad, CA). The cDNA was synthesized from total 
RNA with the use of an Advantage cDNA PCR Kit (Clontech, Palo Alto, CA). We 
quantitatively analyzed the expression levels of mRNAs for CXCL10 and GAPDH using an 
ABI Prism 7000 Sequence Detection System (Applied Biosystems Japan, Tokyo) and 
TaqMan® Universal PCR Master Mix (Applied Biosystems) and Assays-on-Demand™ Gene 
Expression Products (Applied Biosystems) according to the manufacturer's recommendations. 
The thermal cycler protocol was: 95°C for 10 min, followed by 40 cycles of 95°C for 5 
s and 60°C for 30 s. We performed an analysis of the relative gene expression data using the 
2−ΔΔCT method on Sequence Detection System Software (Applied Biosystems). We calculated 
the fold change in the studied gene expression, normalized to an endogenous control, using 
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the formula RQ = 2−ΔΔCT. The relative expression levels of CXCL10 mRNAs are expressed as 
a fold increase in the GAPDH mRNA expression. 
 
Protein isolation and Western blot analysis 
The cells were treated with 10 ng/ml IFN-γ for 5, 10, 30, 60, 120, or 240 min in the 
presence or absence of cepharanthine (10 μg/ml). Whole-cell lysates were prepared using 
M-PER lysis solution (Thermo Fisher Scientific, Waltham, MA) supplemented with a 
protease/phosphatase inhibitor mixture (Thermo Fisher Scientific). Cytosolic extracts (30 μg) 
were subjected to electrophoresis on 10% sodium dodecyl sulfate (SDS)-polyacrylamide gels 
(Bio-Rad, Hercules, CA), and then transferred onto nitrocellulose membranes. The 
membranes were blocked with 3% bovine serum albumin (BSA) and incubated with each of 
the following antibodies (all from Cell Signaling Technology, Beverly, MA, diluted at 
1:1000): anti-Janus kinase 1 (JAK1), anti-Phospho-JAK1, anti-JAK2, anti-Phospho-JAK2, 
anti-STAT1, anti- Phospho-STAT1, and anti-β-actin. After intervening rinses with Tris 
buffered saline with Tween 20 (TBS-T), the IgG secondary antibodies (Cell Signaling 
Technology, diluted at 1:1000) were used for the respective primary antibodies. The immune 
complexes were visualized by enhanced chemiluminescence (ECL) Western Blotting 
Detection Reagent (GE Healthcare, Buckinghamshire, UK). The density of the visualized 
immune complexes was digitized using an Amersham Imager 600 (GE Healthcare). 
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Cell migration assay 
We analyzed Jurkat cells' directional migration, which was induced by conditioned 
medium (CM) derived from IFN-γ-treated NS-SV-DC cells, using a CytoSelect™ 96-well 
Cell Migration Assay (5 µm, Fluorometric Format, Cell Biolabs, San Diego, CA) according to 
the manufacturer's instructions. In brief, NS-SV-DC cells were treated with 10 ng/ml IFN-γ in 
the presence or absence of cepharanthine (1 or 10 μg/ml) for 24 h, and then 150 µl of CM was 
placed in the wells of the bottom (feeder tray). Next, 100 µl of serum-free medium containing 
5105 Jurkat cells was placed in the migration chamber. The chemotaxis plate was cultured at 
37°C for 12 h. After incubation, the cells that had migrated to the lower chambers were 
incubated for 20 min with 50 µl of Lysis Buffer/Dye Solution (Cell Biolabs). Fluorescence 
was read at 480/520 nm. Values were expressed as relative fluorescence units (RFU). The 
experiments were performed in triplicate. 
 
Statistical analysis 
The statistical analysis was performed by Mann-Whitney U-test, and p-values <0.05 
were considered significant. 
 
RESULTS 
Cell viability assay of cepharanthine-treated NS-SV-DC and NS-SV-AC cells 
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We used an MTT assay to determine the growth kinetics of NS-SV-DC and NS-SV-AC 
cells treated with various concentrations of cepharanthine for up to 3 days. The cell growth of 
these two cell lines decreased at concentrations of 20–50 μg/ml of cepharanthine (Fig, 1). We 
thus used cepharanthine at the concentrations up to 10 μg/ml in the subsequent experiments. 
 
IFN-γ-induced CXCL10 production in NS-SV-DC cells 
We conducted the ELISA assay to examine the production of CXCL10 after treatment 
with 10 ng/ml of IFN-γ for 24 h in NS-SV-DC and NS-SV-AC cells. As shown in Figure 2a, a 
significant increase in the production of CXCL10 protein was detected in NS-SV-DC cells, 
but not in NS-SV-AC cells. We also examined the production of CXCL10 in NS-SV-DC cells 
by ELISA assay after treatment with 1, 10, 50, and 100 ng/ml of IFN-γ for 24 h. Figure 2b 
shows that the CXCL10 production was increased by treatment with IFN-γ in a 
dose-dependent manner. 
 
Cepharanthine inhibited the IFN-γ-induced CXCL10 production in NS-SV-DC cells 
To identify the effect of cepharanthine on the IFN-γ-induced CXCL10 expression at the 
mRNA level, we treated NS-SV-DC cells with 0.1, 1, and 10 μg/ml of cepharanthine under 
stimulation of 10 ng/mL of IFN-γ for 12 h. As shown in Figure 3a, cepharanthine (0.1–10 
μg/ml) significantly suppressed the level of IFN-γ-induced CXCL10 mRNA in NS-SV-DC 
cells. 
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We then examined CXCL10 protein expression using an ELISA assay. NS-SV-DC cells 
were treated with 10 ng/ml of IFN-γ in the presence of 0.1, 1, or 10 μg/ml of cepharanthine 
for 24 h. As a consequence, the IFN-γ-induced CXCL10 protein was significantly suppressed 
by cepharanthine (Fig. 3b). 
 
Effects of cepharanthine on the JAK2/STAT1 and NF-κB signaling pathways in 
IFN-γ-stimulated NS-SV-DC cells 
IFN-γ is known to activate the JAK/STAT signaling kinases to regulate gene expression 
[23]. We thus evaluated the effects of cepharanthine on IFN-γ-induced JAK1, JAK2 and 
STAT1 activation in NS-SV-DC cells. The cells were treated with 10 ng/ml of IFN-γ in the 
presence or absence of cepharanthine (10 μg/ml). The Western blot analysis demonstrated that 
phospho-JAK2 and phospho-STAT1 were significantly increased after IFN-γ stimulation in 
NS-SV-DC cells (Fig. 4a), whereas the expression of JAK1 was not observed in NS-SV-DC 
cells (data not shown). In contrast, cepharanthine treatment led to a reduction in 
IFN-γ-induced JAK2 and STAT1 phosphorylation in NS-SV-DC cells (Fig. 4a, b). 
Since CXCL10 gene contains NF-κB and STAT1-responsible elements (ISRE; 
interferon-stimulated response element) in the promoter regions [24], we next attempted to 
examine the effect of cepharanthine on NF-κB signaling in NS-SV-DC cells. However, we 
could not identify NF-κB activation by IFN-γ stimulation in this cell line; i.e., the degradation 
of IκB-α and the translocation of p65 to the nucleus were not detected in 
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IFN-γ-stimulated-NS-SV-DC cells (data not shown). This result was consistent with our 
previous observation that NF-κB activation was not detected in NS-SV-DC cells due to the 
lack of IκB-α protein and mRNA [25]. 
 
Effects of cepharanthine on the chemotaxis of Jurkat T cells 
Since CXCL10 has been reported to accumulate CXCR3+ T cells in lip salivary glands 
(LSGs) of SS patients [13], we analyzed the ability of cepharanthine to recruit Jurkat T cells 
in IFN-γ-treated NS-SV-DC cells. The migration assay results demonstrated that the 
chemotaxis of Jurkat cells was significantly increased in IFN-γ-treated NS-SV-DC cells 
compared to IFN-γ-untreated NS-SV-DC cells (Fig. 5). In addition, cepharanthine 
significantly inhibited the IFN-γ-mediated chemotaxis of Jurkat cells (Fig. 5). These results 
indicated that cepharanthine has the potential to inhibit the chemotaxis of CXCR3+ T cells 
through the inhibition of CXCL10. 
 
DISCUSSION 
We focused on the effects of cepharanthine on the expression of CXCL10, an IFN-γ 
inducible chemokine the transcriptional activation of which is dependent mainly on the 
JAK/STAT1 signaling pathway. Our findings demonstrated, for the first time to our 
knowledge, the anti-inflammatory effects of cepharanthine on IFN-γ-treated human salivary 
gland cells. 
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IFN-γ is one of the key cytokines involved in many inflammatory responses, including 
rheumatic diseases [26]. It is established that IFN-γ treatment can result in CXCL10 
overexpression in some cells, which leads to the migration of CXCR3+ T cells [27, 28]. An 
immunohistochemical study also indicated that IFN-γ stimulated the production of CXCL10 
in salivary ductal glands of SS patients [13]. Here we investigated the precise molecular 
mechanisms involved in the expression of IFN-γ-induced CXCL10 by using immortalized 
human salivary gland cell clones in an in vitro experiment. Our results demonstrated a 
significant increase in the expression of CXCL10 after treatment with IFN-γ only in human 
salivary gland ductal (NS-SV-DC) cells, not in human salivary gland acinar (NS-SV-AC) 
cells. 
We recently reported that our single-center open-label study showed efficacy of 
cepharanthine on the increase of salivary flow in pSS patients [21]. The histology of LSGs 
from SS patients demonstrated that the levels of infiltrated lymphocytes were decreased after 
the oral administration of cepharanthine (6 mg/day for 12 months). Although the precise 
molecular mechanism was not investigated in that study, we speculated that cepharanthine 
may have an effect on CXCL10, which was produced from salivary gland ductal cells by 
IFN-γ. 
In the present study, we observed that the IFN-γ-induced CXCL10 production in 
NS-SV-DC cells was inhibited by cepharanthine. IFN-γ induced the rapid phosphorylation of 
both JAK2 and STAT1 in NS-SV-DC cells, whereas the phosphorylation of both JAK2 and 
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STAT1 was inhibited by cepharanthine treatment. In NS-SV-DC cells, JAK1 was not detected 
by Western blotting. These results suggested that cepharanthine inhibits the IFN-γ-induced 
CXCL10 expression in NS-SV-DC cells through the suppression of the activation of the 
JAK2/STAT1 pathway. 
It was reported that CXCL10 gene contains NF-κB and STAT1-responsible elements 
(ISRE) in the promoter regions [24]. In addition, IFN-γ was reported to potentiate 
TNF-α-induced CXCL10 production in human monocytes by increasing the activation of 
STAT1 and NF-κB through JAK1 and JAK2 pathways [29]. We also attempted to study the 
effect of cepharanthine on NF-κB signaling, but we did not observe NF-κB activation by 
IFN-γ in NS-SV-DC cells. In the Western blot analysis, IκB-α degradation and the 
translocation of p65 to the nucleus were not detected in IFN-γ-stimulated NS-SV-DC cells. 
These results are consistent with our previous report [25]. 
Taken together, these observations indicate that IFN-γ potentiates CXCL10 production 
in human salivary ductal cells by the activation of the JAK2/STAT1 signaling pathway, not 
by the NF-κB pathway, and that cepharanthine suppresses the IFN-γ-induced CXCL10 
production via an inhibition of the JAK2/STAT1 signaling. 
Chemokines are a superfamily of cytokines that regulate immune cell migration under 
both inflammatory and normal physiological conditions [30]. The interactions between 
chemokines and their receptors play an important role in the induction of a selective local 
infiltration of specific cells in various diseases [31]. It was reported that CXCL10 was 
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expressed in the salivary ductal glands of SS patients and that CXCL10 was accumulated in 
CXCR3+ T cells in LSGs of SS patients [13]. In the present study, the migration of Jurkat 
cells, a human acute T-cell leukemia cell line, was stimulated in response to the conditioned 
medium obtained from IFN-γ-treated NS-SV-DC cells. This finding is consistent with the 
histological findings of SS salivary glands; i.e., a periductal infiltration of T cells was evident 
in salivary glands of SS patients. Thus, cepharanthine significantly inhibited the 
IFN-γ-mediated chemotaxis of Jurkat T cells. These results suggest that cepharanthine could 
contribute to the inhibition of T cells' chemotaxis through the down-regulation of CXCL10, 
which is secreted from salivary gland ductal cells following IFN-γ stimulation. 
In conclusion, the results of this study demonstrated that cepharanthine suppresses 
IFN-γ-induced CXCL10 expression via an inhibition of the JAK2/STAT1 signaling pathway 
in human salivary gland ductal cells. Our findings also indicate that cepharanthine inhibits the 
chemotaxis of Jurkat T cells by reducing the CXCL10 production from ductal cells. These 
results suggest that cepharanthine could be a potential therapeutic drug for pSS patients. 
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 FIGURE LEGENDS 
 
Fig. 1. Growth inhibitory effect of cepharanthine on NS-SV-DC and NS-SV-AC cells. 
NS-SV-DC Cells (a) and NS-SV-AC cells (b) (1×104 cells/ well) were seeded into 96-well 
plates. After 24 h, cells were treated with cepharanthine (0.1–-50 μg/ml). At different time 
intervals, cell growth was evaluated by MTT assay. Bar: mean ± SD. *p<0.05. **p<0.01. 
 
Fig. 2. CXCL10 production following IFN-γ stimulation. a: NS-SV-DC and NS-SC-AC 
cells were treated with IFN-γ (10 ng/ml) for 6, 12, or 24 h. An ELISA was performed to 
measure CXCL10 protein in the conditioned medium. Bar: mean ± SD. *p<0.05. b: 
NS-SV-DC cells were treated with 1, 10, 50, or 100 ng/ml of IFN-γ for 24 h. An ELISA was 
performed to measure CXCL10 protein in the conditioned medium. Bar: mean ± SD. *p<0.05. 
 
Fig. 3. Cepharanthine inhibited the IFN-γ-induced CXCL10 production in NS-SV-DC 
cells. a: NS-SV-DC cells were treated with IFN-γ (10 ng/ml) in the presence or absence of 
cepharanthine (0.1–10 μg/ml). for 12 h. Total RNAs were prepared, and the quantification of 
mRNA levels was evaluated by qRT-PCR. Bar: mean ± SD. *p<0.05. b: NS-SV-DC cells 
were treated with IFN-γ (10 ng/ml) in the presence or absence of cepharanthine (0.1–10 
μg/ml) for 24 h. An ELISA was performed to measure the CXCL10 protein in the conditioned 
medium. Bar: mean ± SD. *p<0.05. 
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 Fig. 4. Effects of cepharanthine on the JAK2/STAT1 pathway in IFN-γ-stimulated 
NS-SV-DC cells. a: The NS-SV-DC cells were treated with 10 ng/ml of IFN-γ in the presence 
or absence of cepharanthine (10 μg/ml). A Western blot analysis showed that the 
phosphorylation of JAK2 and STAT1 were increased after IFN-γ stimulation in NS-SV-DC 
cells. b: The bar graphs of phospho-JAK2 or phospho-STAT1 expression were normalized to 
β-actin. 
 
Fig. 5. Effects of cepharanthine on the chemotaxis of Jurkat T cells. NS-SV-DC cells 
were treated with 10 ng/ml IFN-γ in the presence or absence of cepharanthine (10 μg/ml) for 
24 h. Serum-free Jurkat cells were placed in the migration chamber. The chemotaxis plate was 
incubated at 37°C for 12 h. Fluorescence was read at 480/520 nm. Values were expressed as 
relative fluorescence units (RFU). Bar: mean ± SD. *p<0.05. 
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